The role of IPSS-m in predicting survival and relapse after allogeneic HSCT for MDS: A single center experience.
All trial regimens evaluated were safe, but the five-day regimen offered the best balance of safety and efficacy ORLANDO, DECEMBER 7, 2025 – Patients with lower-risk myelodysplastic syndromes (MDS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results